Cargando…

The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation

Preventing thromboembolic events, while minimizing bleeding risks, remains challenging when managing patients with atrial fibrillation (AF). Several factors contribute to current dosing patterns of nonvitamin K antagonist oral anticoagulants (NOACs), including patient characteristics, comorbidities,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beyer-Westendorf, Jan, Fay, Matthew, Amara, Walid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382498/ https://www.ncbi.nlm.nih.gov/pubmed/34435170 http://dx.doi.org/10.1055/s-0041-1731777

Ejemplares similares

Tackling Nonatrial Fibrillation Diseases Using Nonvitamin K Antagonist Oral Anticoagulant: by What and for Whom?
por: Kim, Jong S.
Publicado: (2019)

The change of renal functions after nonvitamin K oral anticoagulants in patients with atrial fibrillation
por: Chantrarat, Thoranis, et al.
Publicado: (2021)

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
por: Blann, Andrew
Publicado: (2015)

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
por: Brown, Karen S., et al.
Publicado: (2016)

Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants
por: Morimoto, Yoshinari, et al.
Publicado: (2016)

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
por: Turpie, Alexander G.G., et al.
Publicado: (2017)

Real‐world use of nonvitamin K antagonist oral anticoagulant in atrial fibrillation patients with liver disease: A meta‐analysis
por: Dai, Qixin, et al.
Publicado: (2020)

Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study
por: Han, Sola, et al.
Publicado: (2021)

Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants
por: Sarah, Lessire, et al.
Publicado: (2014)

Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity‐Weighted Cohort Study
por: Søgaard, Mette, et al.
Publicado: (2019)

Erratum to “Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants”
por: Lessire, Sarah, et al.
Publicado: (2014)

Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment
por: Wilke, Thomas, et al.
Publicado: (2019)

Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants
por: Gallù, Mariacarla, et al.
Publicado: (2020)

Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2019)

Correction: Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
Publicado: (2019)

Optimal nonvitamin K antagonist oral anticoagulant therapy in a warfarin-sensitive patient after left atrial appendage closure: A case report
por: Shen, Long, et al.
Publicado: (2018)

Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation
por: Saliba, Walid
Publicado: (2015)

Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection
por: Mustanoja, Satu, et al.
Publicado: (2015)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

A Comparison among Nonvitamin K Antagonist Oral Anticoagulants in Asian Patients with Venous Thromboembolism: A Multi-Institutional Study
por: Tsai, Ming-Lung, et al.
Publicado: (2022)

Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS(2) score ⩾ 2
por: Fernandez, Maria M, et al.
Publicado: (2015)

Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration
por: Zhao, Shujuan, et al.
Publicado: (2020)

Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
por: Caturano, Alfredo, et al.
Publicado: (2019)

Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease
por: Posch, Florian, et al.
Publicado: (2019)

The importance of use of appropriate anticoagulant in atrial fibrillation after gastric bypass surgery
por: Nasser, Mohamed Farhan, et al.
Publicado: (2021)

Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT‐AF II
por: Yao, Ren Jie Robert, et al.
Publicado: (2023)

Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
por: Zawawi, Nur Azyyati, et al.
Publicado: (2021)

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

Difference between the Upper and the Lower Gastrointestinal Bleeding in Patients Taking Nonvitamin K Oral Anticoagulants
por: Maruyama, Kyohei, et al.
Publicado: (2018)

Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment
por: Zhang, Rong-feng, et al.
Publicado: (2021)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation
por: Seiffge, David J., et al.
Publicado: (2019)

Ten years of non-vitamin K antagonists oral anticoagulants for stroke prevention in atrial fibrillation: is warfarin obsolete?
por: Hammwöhner, Matthias, et al.
Publicado: (2020)

Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention
por: Gorczyca, Iwona, et al.
Publicado: (2019)

Nonvitamin K oral anticoagulants with proton pump inhibitor cotherapy ameliorated the risk of upper gastrointestinal bleeding
por: Chaiyana, Parata, et al.
Publicado: (2023)

Effectiveness and Safety of Off-label Dosing of Non–vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients
por: Lee, Kwang-No, et al.
Publicado: (2020)

Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2022)

Asian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral Anticoagulants
por: Bang, Oh Young, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0r34u526anb42bcerupoiffhh8